Cargando…

Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy

Heavily-treatment-experienced people living with human immunodeficiency virus (HTE-PLWH) represent a population with limited therapeutic options and at high-risk of clinical progression, morbidity, and mortality. The development of new drugs and new drug classes for the treatment of HIV-1 infection...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muccini, Camilla, Canetti, Diana, Castagna, Antonella, Spagnuolo, Vincenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800563/ https://www.ncbi.nlm.nih.gov/pubmed/35115764 http://dx.doi.org/10.2147/DDDT.S273660

Ejemplares similares

Achieving virological control in pan-resistant HIV-1 infection: A case series
por: Canetti, Diana, et al.
Publicado: (2022)

Increasing trend of transmitted integrase inhibitor resistance in a cohort of antiretroviral therapy-naive people living with HIV
por: Muccini, Camilla, et al.
Publicado: (2023)

Fostemsavir for HIV-1 infection
Publicado: (2022)

Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1
por: Ackerman, Peter, et al.
Publicado: (2021)

Association between low levels of HIV-1 DNA and HLA class I molecules in chronic HIV-1 infection
por: Muccini, Camilla, et al.
Publicado: (2022)

Increasing incidence and prevalence of metabolic syndrome in people living with HIV during the COVID-19 pandemic
por: Papaioannu Borjesson, Rebecka, et al.
Publicado: (2023)

Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients
por: Gianotti, Nicola, et al.
Publicado: (2017)

Innovation in the discovery of the HIV-1 attachment inhibitor temsavir and its phosphonooxymethyl prodrug fostemsavir
por: Wang, Tao, et al.
Publicado: (2021)

Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1
por: Aberg, Judith A., et al.
Publicado: (2023)

Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSense(®) Entry assay
por: Gartland, Margaret, et al.
Publicado: (2020)

Lenacapavir with Fostemsavir in a Multidrug-Resistant HIV-Infected Hemodialysis Patient
por: Bigirimana, Ferdinand, et al.
Publicado: (2023)

Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid‐dependent, human immunodeficiency virus seronegative participants
por: Moore, Katy, et al.
Publicado: (2019)

Monkeypox in a patient with undifferentiated connective tissue disease
por: Clemente, Tommaso, et al.
Publicado: (2022)

Pharmacokinetics of Temsavir, the Active Moiety of the Prodrug Fostemsavir, in Subjects with Hepatic Impairment
por: Sevinsky, Heather, et al.
Publicado: (2017)

Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals
por: Anderson, Sarah-Jane, et al.
Publicado: (2021)

2500. Fostemsavir Drug–Drug Interaction Profile, an Attachment Inhibitor and Oral Prodrug of Temsavir, for Heavily Treatment Experienced HIV-1-Infected Patients
por: Moore, Katy P, et al.
Publicado: (2019)

Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir
por: Lataillade, Max, et al.
Publicado: (2018)

Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1
por: Gartland, Margaret, et al.
Publicado: (2022)

547. Results of Patient-Reported Outcome Data From the Phase III BRIGHTE Study of Fostemsavir
por: Proudfoot, Clare, et al.
Publicado: (2018)

Incidence and Predictors of Serological Treatment Response in Early and Late Syphilis Among People Living With HIV
por: Spagnuolo, Vincenzo, et al.
Publicado: (2018)

Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants
por: Moore, Katy, et al.
Publicado: (2022)

1315. No Dose Adjustment of Metformin with Fostemsavir Coadministration Based on Mechanistic Static and Physiologically Based Pharmacokinetic Models
por: Nguyen, Dung N, et al.
Publicado: (2020)

Necroptosis Takes Place in Human Immunodeficiency Virus Type-1 (HIV-1)-Infected CD4(+) T Lymphocytes
por: Pan, Ting, et al.
Publicado: (2014)

Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients
por: Spagnuolo, Vincenzo, et al.
Publicado: (2017)

365. Durable efficacy and robust CD4+ T-cell count improvement observed across age, race, sex, and geographic subgroups of heavily treatment-experienced people with multidrug-resistant HIV-1 after 240 weeks of fostemsavir treatment
por: Dyson, Alftan, et al.
Publicado: (2023)

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2019)

834. Characterization of Heavily Treatment Experienced HIV-1 Infected Clinical Trial Participants Infected with SARS-CoV-2 COVID 19: Fostemsavir BRIGHTE Phase 3 Clinical Trial
por: Chabria, Shiven, et al.
Publicado: (2021)

Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy
por: Gianotti, Nicola, et al.
Publicado: (2015)

Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2014)

Green-adapted spectrophotometric determination of fostemsavir based on selective bromophenol blue extraction; reduction of hazardous consumption using computational calculations
por: Batubara, Afnan S., et al.
Publicado: (2023)

Predictors of lack of serological response to syphilis treatment in HIV-infected subjects
por: Spagnuolo, Vincenzo, et al.
Publicado: (2014)

Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors
por: Ripa, Marco, et al.
Publicado: (2021)

Effects of Temsavir, Active Moiety of Antiretroviral Agent Fostemsavir, on QT Interval: Results From a Phase I Study and an Exposure–Response Analysis
por: Lagishetty, Chakradhar, et al.
Publicado: (2020)

People and places
por: Mead, Margaret, 1901-1978
Publicado: (1959)

People and places
por: The Abdus Salam International Centre for Theoretical Physics. Trieste
Publicado: (2001)

Characteristics of HIV pre-exposure prophylaxis users at first PrEP counselling visit: the CSL-PrEP cohort
por: Nozza, Silvia, et al.
Publicado: (2022)

Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients
por: Gianotti, Nicola, et al.
Publicado: (2017)

Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infection
por: Stellbrink, Hans-Jürgen
Publicado: (2010)

Monkeypox infection among men who have sex with men: PCR testing on seminal fluids
por: Raccagni, Angelo Roberto, et al.
Publicado: (2022)

Breakthrough monkeypox infection among individuals previously immunized with smallpox or monkeypox vaccination
por: Raccagni, Angelo Roberto, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g16tf5gvo8u6jrej765ti4psli